Evidence map›Paper›PMID 29879271›Full record

ArticleJAMA oncology2018

Incidence of Diabetes After Cancer Development: A Korean National Cohort Study.

Yul Hwangbo, Danbee Kang, Minwoong Kang, Saemina Kim, Eun Kyung Lee, Young Ae Kim, Yoon Jung Chang, Kui Son Choi, So-Youn Jung, Sang Myung Woo and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in JAMA oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed, 5 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 5 syntheses or guidelines pooled it, 156 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 3 countries.

Yul HwangboDivision of Endocrinology, Department of Internal Medicine, National Cancer Center, Goyang, South Korea.
Danbee KangDepartment of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea.
Minwoong KangCenter for Clinical Epidemiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Saemina KimCenter for Clinical Epidemiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Eun Kyung LeeDivision of Endocrinology, Department of Internal Medicine, National Cancer Center, Goyang, South Korea.
Young Ae KimNational Cancer Control Institute, National Cancer Center, Goyang, South Korea.
Yoon Jung ChangNational Cancer Control Institute, National Cancer Center, Goyang, South Korea.
Kui Son ChoiDepartment of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, South Korea.
So-Youn JungCenter for Breast Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Sang Myung WooCenter for Liver Cancer, National Cancer Center, Goyang, South Korea.
Jin Seok AhnDivision of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Sung Hoon SimCenter for Breast Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Yun Soo HongDepartment of Epidemiology, and Welch Center for Epidemiology, Prevention, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Roberto Pastor-BarriusoNational Center for Epidemiology, Instituto de Salud Carlos III, and Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Eliseo GuallarDepartment of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea.
Eun Sook LeeDepartment of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, South Korea.
Sun-Young KongDepartment of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, South Korea.
Juhee ChoDepartment of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea.
National Cancer Center · KRSamsung Medical Center · KRSungkyunkwan University · KRInstituto de Salud Carlos III · ESJohns Hopkins University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Diabetes is an established risk factor for developing cancer. A limited body of evidence also suggests that cancer can increase the risk of developing new cases of diabetes, but the evidence is inconclusive. Objective: To evaluate whether the development of cancer is associated with increasing risk of subsequent diabetes. Design, Setting, and Participants: This cohort study included a nationally representative sample of the Korean general population observed for up to 10 years (January 1, 2003, to December 31, 2013). A total of 524 089 men and women 20 to 70 years of age without diabetes and with no history of cancer at baseline were included. Exposures: Incident cancer (time-varying exposure). Main Outcomes and Measures: Incident type 2 diabetes using insurance claim codes. Results: During 3 492 935.6 person-years of follow-up (median follow-up, 7.0 years) in 494 189 individuals (50.0% female; mean [SD] age, 41.8 [12.5] years), 15 130 participants developed cancer and 26 610 participants developed diabetes. After adjustment for age, sex, precancer diabetes risk factors, metabolic factors, and comorbidities, the hazard ratio (HR) for diabetes associated with cancer development was 1.35 (95% CI, 1.26-1.45; P < .001). The excess risk for diabetes was highest in the first 2 years after cancer diagnosis, but it remained elevated throughout follow-up. By cancer type, development of pancreatic (HR, 5.15; 95% CI, 3.32-7.99), kidney (HR, 2.06; 95% CI, 1.34-3.16), liver (HR, 1.95; 95% CI, 1.50-2.54), gallbladder (HR, 1.79; 95% CI, 1.08-2.98), lung (HR, 1.74; 95% CI, 1.34-2.24), blood (HR, 1.61; 95% CI, 1.07-2.43), breast (HR, 1.60; 95% CI, 1.27-2.01), stomach (HR, 1.35; 95% CI, 1.16-1.58), and thyroid cancer (HR, 1.33; 95% CI, 1.12-1.59) was associated with a significantly increased risk of diabetes. Conclusions and Relevance: In this large Korean cohort, cancer development increased the risk of subsequent diabetes. These data provide evidence that cancer is associated with an increased risk of diabetes in cancer survivors independent of traditional diabetes risk factors. Physicians should remember that patients with cancer develop other clinical problems, such as diabetes, with higher frequency than individuals without cancer, and should consider routine diabetes screening in these patients.

Indexed as

AdultAgedDiabetes MellitusFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedNeoplasmsPrognosisRepublic of KoreaRetrospective StudiesRisk FactorsYoung Adult

Identifiers

PMID29879271
PMCPMC6143049
OpenAlexW2807038152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.